Finally, in the 2019 cohort, other classes of antidiabetic drugs, in particular those AD, such as GLP-1-RA and SGLT-2i, that are more recently recommended by clinical guidelines for the management of patients with comorbidities or at high risk of developing cardiovascular complications were prescribed to a handful of patients (i.e., less than 2% of the population). The gene discussed is GLP1R; the disease is Alzheimer disease.